Insulin Pumps: Managing Diabetes with Precision and Convenience
Approximately 350,000 Americans rely on insulin pumps to manage their diabetes, with 90% having type 1 and 10% having type 2. These innovative devices, worn for 2 to 4 days, mimic the pancreas by delivering insulin continuously and on demand.
Insulin pumps have evolved significantly, now offering automatic basal and bolus adjustments based on continuous glucose monitor (CGM) data, touchscreens, waterproofing, and Bluetooth connectivity. They consist of a display screen, insulin reservoir, and a thin cannula inserted under the skin. Popular models include Medtronic Minimed 780G and 770G, Omnipod 5, Tandem t:slim X2, and Tandem Mobi.
While providing precise insulin doses and eliminating daily injections, pumps also come with drawbacks such as higher cost, learning curve, and potential malfunctions. It's crucial to learn proper use from a healthcare professional, including attaching the infusion set, changing insulin, and troubleshooting.
By 2025, the U.S. market will see the Tandem t:slim X2 with Control-IQ+ technology paired with Dexcom G6 sensors, and the newer, smaller Tandem Mobi. Roche's Accu-Chek Solo micropump and the Dana-i system with Dexcom G6 are expected to launch in late 2024. The Eversense E3 CGM has also received integrated CGM status for use with insulin pumps.
Insulin pumps offer precision and convenience in diabetes management, with continuous innovation in technology and features. However, they require careful use and consideration of their pros and cons. As new models and updates emerge, people with diabetes will have more options to find the best fit for their needs.
